Paratek Pharmaceuticals (NASDAQ:PRTK) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a hold rating to a buy rating in a research note released on Thursday, ValuEngine reports.

Several other equities research analysts have also recently weighed in on the stock. WBB Securities assumed coverage on shares of Paratek Pharmaceuticals in a research report on Wednesday, January 8th. They issued a buy rating and a $6.00 price objective for the company. BTIG Research set a $36.00 price objective on shares of Paratek Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, December 18th. HC Wainwright restated a buy rating on shares of Paratek Pharmaceuticals in a research report on Wednesday, February 26th. Canaccord Genuity assumed coverage on shares of Paratek Pharmaceuticals in a research report on Thursday, January 2nd. They issued a buy rating and a $14.00 price objective for the company. Finally, SVB Leerink restated an outperform rating on shares of Paratek Pharmaceuticals in a research report on Monday, January 27th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Paratek Pharmaceuticals has a consensus rating of Buy and a consensus price target of $14.92.

PRTK stock traded up $0.64 during trading on Thursday, hitting $3.85. 940,400 shares of the stock traded hands, compared to its average volume of 927,095. Paratek Pharmaceuticals has a one year low of $2.50 and a one year high of $6.39. The stock has a market cap of $135.53 million, a price-to-earnings ratio of -0.98 and a beta of 1.35. The company has a 50 day simple moving average of $3.61 and a 200 day simple moving average of $3.63.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Tuesday, February 25th. The specialty pharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.22. Paratek Pharmaceuticals had a negative net margin of 778.47% and a negative return on equity of 5,327.73%. The firm had revenue of $8.97 million during the quarter, compared to the consensus estimate of $4.78 million. As a group, research analysts forecast that Paratek Pharmaceuticals will post -2.47 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp grew its holdings in Paratek Pharmaceuticals by 4.9% during the third quarter. State Street Corp now owns 673,779 shares of the specialty pharmaceutical company’s stock valued at $2,911,000 after purchasing an additional 31,526 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. acquired a new position in Paratek Pharmaceuticals during the fourth quarter valued at approximately $302,000. Charles Schwab Investment Management Inc. grew its holdings in Paratek Pharmaceuticals by 4.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 201,028 shares of the specialty pharmaceutical company’s stock valued at $811,000 after purchasing an additional 8,145 shares during the period. California Public Employees Retirement System grew its holdings in Paratek Pharmaceuticals by 5.8% during the third quarter. California Public Employees Retirement System now owns 122,000 shares of the specialty pharmaceutical company’s stock valued at $527,000 after purchasing an additional 6,700 shares during the period. Finally, Rhumbline Advisers grew its holdings in Paratek Pharmaceuticals by 10.4% during the fourth quarter. Rhumbline Advisers now owns 49,034 shares of the specialty pharmaceutical company’s stock valued at $198,000 after purchasing an additional 4,616 shares during the period. Hedge funds and other institutional investors own 54.23% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Recommended Story: What is an inverted yield curve?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.